Pittsburgh, PA (September 15, 2003). Cellomics, Inc., the creator and market leader of High Content Screening (HCS), announced today that the US Patent Office has issued US patent number 6,620,591 covering the automated methods for detecting the translocation of a cellular component of interest between a first cellular compartment and a second cellular compartment on and/or within individual cells.
This issuance adds to Cellomics Inc portfolio of global patents which include both broad claims to HCS technology as well as specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. Cellomics has twenty-eight additional patents that have been allowed or are currently pending in the field of HCS. In addition, Cellomics has separate patent estates for the CellChip(tm) system, the miniaturized cell analysis platform of the future, and a variety of fluorescence-based biosensors that are live reporters of the function, activity, or environment of intracellular targets. "The patent position of Cellomics continues to grow in the emerging market of High Content Screening", stated Dr. Jeffrey R. Haskins, VP of Assay Development. "Cellomics invested heavily in the development and patenting of the technologies we created and our patent portfolio places us in the leadership position." "Cellomics has initiated a licensing program to broaden the availability of HCS to other biotools and biotechnology companies", stated Daniel J. Calvo, President and CEO of Cellomics. "Our desire is to help to broaden the growth of the market through our licensing program". Cellomics, Inc. is pioneering the field of cellular knowledge extraction. Its unique technology integrates fluorescence-based reagents, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetic systems), and informatics tools to achieve a flexible, broadly applicable platform for users in the life sciences. This automated platform, when applied to early drug discovery is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as reducing the cycle time in basic research. Cellomicsˇ¦ proprietary platform including the ArrayScan(R)and KineticScan(R) HCS Readers, along with its vHCS(tm) Discovery Toolbox software and automated analysis applications, are in use at multiple sites within the top fifteen pharmaceutical companies in the world, as well as leading pharmaceutical and biotechnology companies and academic centers globally.
For further information, contact:
Judy P. Masucci, PhD Director, Marketing Cellomics, Inc. 100 Technology Drive Pittsburgh, PA 15219 412.770.2353 412.770.2450 (fax)
Last Updated ( Monday, 21 June 2004 )
Upcoming Events
December 13, 2008 ASCB 2008 Please visit our booth at the 49th Annual Meeting of the American Society for Cell Biology ...
Home 
Cellomics Granted Key US Patent
Pittsburgh, PA (September 15, 2003). Cellomics, Inc., the creator and market leader of High Content Screening (HCS), announced today that the US Patent Office has issued US patent number 6,620,591 covering the automated methods for detecting the translocation of a cellular component of interest between a first cellular compartment and a second cellular compartment on and/or within individual cells.
This issuance adds to Cellomics Inc portfolio of global patents which include both broad claims to HCS technology as well as specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. Cellomics has twenty-eight additional patents that have been allowed or are currently pending in the field of HCS. In addition, Cellomics has separate patent estates for the CellChip(tm) system, the miniaturized cell analysis platform of the future, and a variety of fluorescence-based biosensors that are live reporters of the function, activity, or environment of intracellular targets. "The patent position of Cellomics continues to grow in the emerging market of High Content Screening", stated Dr. Jeffrey R. Haskins, VP of Assay Development. "Cellomics invested heavily in the development and patenting of the technologies we created and our patent portfolio places us in the leadership position." "Cellomics has initiated a licensing program to broaden the availability of HCS to other biotools and biotechnology companies", stated Daniel J. Calvo, President and CEO of Cellomics. "Our desire is to help to broaden the growth of the market through our licensing program". Cellomics, Inc. is pioneering the field of cellular knowledge extraction. Its unique technology integrates fluorescence-based reagents, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetic systems), and informatics tools to achieve a flexible, broadly applicable platform for users in the life sciences. This automated platform, when applied to early drug discovery is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as reducing the cycle time in basic research. Cellomicsˇ¦ proprietary platform including the ArrayScan(R)and KineticScan(R) HCS Readers, along with its vHCS(tm) Discovery Toolbox software and automated analysis applications, are in use at multiple sites within the top fifteen pharmaceutical companies in the world, as well as leading pharmaceutical and biotechnology companies and academic centers globally.
top